Equity
AbCellera Biologics Inc. (ABCL) perpetual futures
AbCellera Biologics Inc. is a Vancouver-based biotech company (founded 2012) that uses an AI-driven platform to discover antibodies for drug development, collaborating with partners such as Eli Lilly.
-6.9%NASDAQ closed
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:ABCL
Loads TradingView's third-party widget (about 1 MB) on demand.
Auto: underlying reference priceOpen in TradingView
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Venues
1
Live markets
0/1
24h volume
-
Open interest
-
Best liquidity
-
Tightest spread
-
Highest volume
-
Settlement mix
USDT · 1/1
Perp/spot vol.
-
OI / float
-
Spot performance
1D-6.94%
5D-7.16%
1M-6.57%
6M+194.26%
YTD+245.03%
1Y+101.37%
Venue matrix
1 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
BingXTokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| ABCLRobinhood | – | – | – | $6k | Robinhood Chain |
Best venues for this underlying
Best liquidity
-No live data-
Tightest spread
-No live data-
Highest volume
-No live data-
Company data
Company fundamentals
Updated 1h ago
Company data
Company fundamentals
Market cap
$3.8B
Updated 1h ago
Revenue
$66.2M
Trailing 12 months
Revenue growth
-65%
Next fiscal year
Profit margin
-248.8%
P/E
-21.9
Peer P/E 28.1
Free cash flow
-$179.5M
Trailing 12 months
More metrics
Net income
-$164.7M
Trailing 12 months
P/S
57.8
Peer P/E
28.1
Similar listed perps
Revenue estimate
$26.4M
Next fiscal year
Earnings
2026-11-09
Revenue est. $6.2M · Updated 1h ago
Dividend
-
Fundamental detail
Annual + quarterlyLatest revenue$75.1M
Net margin-194.9%
Free cash flow-$174.1M
Net debt$14.7M
PeriodRevenueGrowthNet incomeFCF
2020$233.2M+1,908%$118.9M$8M
2021$375.2M+61%$153.5M$186.1M
2022$485.4M+29%$158.5M$204.7M
2023$38M-92%-$146.4M-$121.4M
2024$28.8M-24%-$162.9M-$187M
2025$75.1M+161%-$146.4M-$174.1M
PeriodGross marginOperating marginNet marginROEROA
2020+88.4%+66.9%+51.0%+14.3%+11.8%
2021+87.9%+54.5%+40.9%+15.0%+11.6%
2022+86.3%+44.6%+32.7%+12.9%+10.3%
2023+100.0%-623.8%-385.0%-12.7%-9.8%
2024+100.0%-1,091.7%-564.8%-15.4%-12.0%
2025+61.6%-289.0%-194.9%-15.1%-10.8%
PeriodCashDebtNet debtCurrent ratio
2020$594.1M$6.8M-$587.3M7.86
2021$476.1M$40.1M-$436.1M7.70
2022$386.5M$82.3M-$304.3M8.67
2023$133.3M$77.4M-$55.9M7.33
2024$156.3M$65.4M-$91M9.81
2025$128.5M$143.2M$14.7M11.32
PeriodMarket capEnterprise valueP/SP/E
2020$10.6B$10B45.489.4
2021$3.9B$3.5B10.525.5
2022$2.9B$2.6B5.918.1
2023$1.7B$1.6B43.4-11.2
2024$862.4M$771.4M29.9-5.3
2025$1B$1B13.6-7.0
PeriodRevenueGrowthNet incomeFCF
Q3 2024$6.5M-1%-$51.1M-$47.6M
Q4 2024$5.1M-45%-$34.2M-$23.6M
Q1 2025$4.2M-57%-$45.6M-$22.2M
Q2 2025$17.1M+133%-$34.7M-$45.8M
Q3 2025$9M+38%-$57.1M-$61.5M
Q4 2025$44.9M+788%-$8.9M-$44.6M
Q1 2026$8.3M+96%-$43.2M-$37.4M
Q2 2026$4.1M-76%-$55.4M-$36M
PeriodGross marginOperating marginNet marginROEROA
Q3 2024+100.0%-1,439.4%-785.4%-4.7%-3.7%
Q4 2024+100.0%-1,440.7%-677.4%-3.2%-2.5%
Q1 2025+100.0%-1,479.6%-1,077.2%-4.5%-3.4%
Q2 2025+100.0%-290.2%-203.3%-3.4%-2.5%
Q3 2025+100.0%-851.8%-637.8%-5.9%-4.2%
Q4 2025+82.3%-63.7%-19.9%-0.9%-0.7%
Q1 2026-4.1%-691.7%-519.1%-4.6%-3.3%
Q2 2026+100.0%-1,550.0%-1,368.6%-6.2%-4.2%
PeriodCashDebtNet debtCurrent ratio
Q3 2024$126.6M$71.4M-$55.2M9.34
Q4 2024$156.3M$65.4M-$91M9.81
Q1 2025$159.3M$67.8M-$91.4M10.15
Q2 2025$92.4M$142.1M$49.6M11.07
Q3 2025$83.2M$142.2M$59.1M10.10
Q4 2025$128.5M$143.2M$14.7M11.32
Q1 2026$77.1M$140.2M$63.1M14.05
Q2 2026$120.1M$135.6M$15.6M12.77
PeriodMarket capEnterprise valueP/SP/E
Q3 2024$766.6M$711.4M117.8-3.8
Q4 2024$863.1M$772.2M170.9-6.1
Q1 2025$663.9M$572.4M156.8-3.7
Q2 2025$1B$1.1B59.9-7.1
Q3 2025$1.5B$1.6B167.9-6.6
Q4 2025$1B$1B22.8-28.5
Q1 2026$1.1B$1.1B127.2-6.2
Q2 2026$2.4B$2.4B592.3-10.9
Refreshed 1h ago
Charts: revenue, profit, cash flow & valuation
CashDebt
Gross marginOperating marginNet margin
P/EP/S
CashDebt
Gross marginOperating marginNet margin
P/EP/S
Next catalyst
Catalysts
Next catalyst
Catalysts
Earnings
2026-11-09
Revenue est. $6.2M · Updated 1h ago
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-0.66$26.4M-65%6
FY 2027-0.73$28.2M-62%6
FY 2028-0.82$29.2M-61%7
FY 2029-0.80$57.6M-23%2
FY 2030-0.67$139.9M+86%4
Q1 2027-0.19$9.9M+18%1
Company events
62026-11-09EarningsActual - / Estimate -0.18-
2026-08-05EarningsActual -0.18 / Estimate -0.16Miss
2026-05-11EarningsActual -0.14 / Estimate -0.22Beat
2026-02-24EarningsActual -0.03 / Estimate -0.18Beat
2025-11-06EarningsActual -0.19 / Estimate -0.17Miss
2025-08-07EarningsActual -0.12 / Estimate -0.17Beat
Peer comparison
Similar listed perpsRevenue mix
PendingSegment data is not available yet.
Analysts
PendingNo analyst data available yet.
Ownership
ABCL-PERPOwnership data is being populated.
Filings
PendingNo filings available yet.
Transcripts
PendingNo transcripts available yet.
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Analyst track record
How the analysts covering ABCL have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 43 | 105 |
| Analysts | 12 | 17 |
| Buy / hold / sell | 41 / 2 / 0 | 98 / 7 / 0 |
| Upgrades / downgrades / initiations | 0 / 1 / 5 | 1 / 2 / 7 |
| Price targets hit / missed | 21 / 13 (62%) | 54 / 23 (70%) |
| Avg. return after a rating (TipRanks) | +23.8% | +37.0% |
| Best / worst call | +217.0% / -57.7% | +217.0% / -57.7% |
After buy calls on this stock: median 21-day move -0.3% vs S&P 500 -2.3% (n = 97)
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Oct 11, 2026 | Unknown AnalystUBS | BuyInitiated | $18.00 | article ↗ |
| Sep 29, 2026 | Brian ChengJ.P. Morgan | BuyInitiated | $17.00 | article ↗ |
| Sep 27, 2026 | Debanjana ChatterjeeJonesTrading | BuyReiterated | $25.00 | article ↗ |
| Sep 27, 2026 | Debanjana ChatterjeeJonesTrading | BuyReiterated | $25.00 | |
| Sep 24, 2026 | Andrea NewkirkGoldman Sachs | HoldInitiated | $13.00 | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data via FMP · computed Oct 16, 2026 · 43 ratings
Embed this asset
<a href="https://perpequities.com/stocks/abcl-perp"><img src="https://perpequities.com/badge/abcl-perp.svg" width="240" height="64" alt="ABCL perpetuals · perpequities.com" loading="lazy"></a>